Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,558
datasets available to search
ShareScore release 0.9.0
Dataset results
34,558 results for “therapy”
dATASET RELATED TO ARTICLE "Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy"
<p><strong>raw data derived by quantification of complement components and activation products in plasma samples of myasthenia gravis (MG) patients positive for anti-achr and anti-musk autoantibodies and healthy controls, using multiplex immunoassays and elisa</strong></p>
Supplementary material - Non-invasive Multimodal Imaging Reveals Early Therapy-Induced Senescence in Human Cancer Cells
<p>The repository features .xls and .txt worksheets including all the data used through this work and reported in the manuscript figures and graphs. More precisely, we included the following: </p> <ul> <li>Figure 2. Raw pixel-wise signals detected in NLO images of TIS cells control cells that were used to perform the colocalization graphs and analyses reported. We describe the average colocalization of SRS and F-CARS signals, and TPEF and E-CARS signals, in both phenotypes.</li> <li>Figure 4. Raw data from image analyses of TPEF and SRS channels of multimodal NLO images, divided in 5 different time points over the therapy follow-up period. The data describe the early rearrangement of mitochondria (TPEF) and lipid vesicles (SRS) in TIS cells, with respect to control counterparts.</li> <li>Figure 6. Raw data from image analyses of QPI images, divided in 4 different time points over the therapy follow-up period. The data describe the early morphological modifications of TIS cells, with respect to control counterparts.</li> </ul>
GDNF gene therapy for alcohol use disorder in male non-human primates
<p>These the minimal data sets that were utilized in analysis and interpretation for the manuscript "GDNF gene therapy treatment for alcohol use disorder" by Matthew Ford et al. These data sets were collected during a study to evaluate the utility of viral-based GDNF expression in the ventral tegmental area to reduce alcohol intake and prevent relapse in a primate model of alcohol use disorder, and ultimately the feasibility of GDNF as a gene therapy for alcohol use disorder. There are data sets on behavior, biochemical analyses, and cyclic voltammetry.</p>
A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.
<p>The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs). <br> While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab.<br> In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control.<br> For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification.</p> <p>In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease.</p> <p>Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).</p>
Dataset on prognostic factors in patients with metastatic castration-resistant prostate cancer undergoing radioligand therapy with [177Lu]Lu-PSMA-617
<p>This upload provides Open Data associated with the publication "Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy" by Gaal S <em>et al.</em> (2023).</p> <p>The upload contains the anonymized dataset of 91 patients analyzed in this publication with all variables that are required to reproduce the results.</p> <p>However, to fully comply with requirements for data anonymization, the patients' age was categorized into groups spanning 5 years each. A dataset with the age variable in exact years can be obtained from the corresponding author (julian.rogasch@charite.de) upon reasonable request.</p> <p>Besides the dataset, this upload provides a dictionary to explain all variables and their categories.</p>
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ClinicalTrials.gov study NCT03635788. IPD Sharing: YES. Countries: 2. Publications: 2.
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
ClinicalTrials.gov study NCT00383708. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
ClinicalTrials.gov study NCT02312258. IPD Sharing: YES. Countries: 35. Publications: 2.
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
ClinicalTrials.gov study NCT00940602. IPD Sharing: YES. Countries: 16. Publications: 1.
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
ClinicalTrials.gov study NCT03345836. IPD Sharing: YES. Countries: 48. Publications: 7.
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Anti
ClinicalTrials.gov study NCT03738215. IPD Sharing: YES. Countries: 7. Publications: 1.
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
ClinicalTrials.gov study NCT03093415. IPD Sharing: YES. Countries: 1. Publications: 7.
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
ClinicalTrials.gov study NCT03005379. IPD Sharing: YES. Countries: 1. Publications: 2.
Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement
ClinicalTrials.gov study NCT03117296. IPD Sharing: NO. Countries: 1. Publications: 3.
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
ClinicalTrials.gov study NCT02038036. IPD Sharing: YES. Countries: 12. Publications: 3.
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Brea
ClinicalTrials.gov study NCT03839823. IPD Sharing: YES. Countries: 13. Publications: 1.
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
ClinicalTrials.gov study NCT03852498. IPD Sharing: YES. Countries: 6. Publications: 1.
Low-Level Laser Therapy for Plantar Fasciitis
ClinicalTrials.gov study NCT05763381. IPD Sharing: YES. Countries: 1. Publications: 36.
Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
ClinicalTrials.gov study NCT00738920. IPD Sharing: YES. Countries: 1. Publications: 3.
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to
ClinicalTrials.gov study NCT01618305. IPD Sharing: YES. Countries: 7. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.